Advances in small molecular inhibitors of IL-6/STAT3 signaling pathway
10.16438/j.0513-4870.2021-0233
- VernacularTitle:IL-6/STAT3信号通路小分子抑制剂的研究进展
- Author:
Li-ping ZHAO
;
Dan-qing SONG
;
Yan-xiang WANG
- Publication Type:Research Article
- Keywords:
interleukin-6;
signal transducer and activator of transcription 3;
inflammatory diseases;
antitumor;
small molecular inhibitor
- From:
Acta Pharmaceutica Sinica
2021;56(9):2472-2484
- CountryChina
- Language:Chinese
-
Abstract:
As a pleiotropic cytokine, interleukin-6 (IL-6) participates in many physiological activities in vivo. IL-6 plays an important role in the physiology and pathology of chronic inflammation, autoimmune diseases, tumors and other diseases through diverse mechanisms. At present, inhibitors targeting IL-6/IL-6R have been shown to improve treatments for some inflammatory diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. IL-6 binds to a specific receptor to activate the downstream JAK/STAT3 signaling pathway. However abnormally activated STAT3 often appears in various types of malignant tumors and participates in the occurrence and development of tumors. In addition, studies have shown that IL-6 is a key factor in the cytokine storm associated with COVID-19 patients. The physiological participation of IL-6/STAT3 pathway in complex diseases makes this pathway become a research hotspot for drug discovery. Therefore, we summarize the latest research progress of small molecular inhibitors on IL-6/STAT3 signaling pathway, in order to provide a reference for the development of IL-6/STAT3 related drug in the future.
